Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy

Xin Wanga Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA

Lacey McIntoshb Division of Oncologic Imaging, Department of Radiology, University of Massachusetts Medical School, Worcester, MA, USA

William J. Selovec Department of Pathology, University of Massachusetts Medical School, Worcester, MA, USA

Jaroslav Zivnyd Division of Gastroenterology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA

Jan Cernye Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USACorrespondence[email protected]

https://orcid.org/0000-0002-6602-5505

Click to increase image sizeClick to decrease image size

Disclosure statement

Dr. Jan Cerny serves on the advisory board/consultancy for Jazz Pharmaceuticals and Amgen. He is a Data and Safety Monitoring Board Member for AlloVir, and holds stocks from Actinium Pharmaceuticals, Bluebird Bio Inc., Dynavax Pharma, Atyr Pharmac, Gamida Cell, Miragen Therapeutics, Mustang Bio, Novavax, Ovid Therapeutics, Sorrento Therapeutics, TG Therapeutics, Vaxart Inc, and Veru Inc., outside the submitted work. The other authors have no other conflicts of interest to declare.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy

Information for

Open access

Opportunities

Help and information

Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature